ReviewEuropean journal of endocrinology2015
Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.
Review in European journal of endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
153 citing papers in PubMed, 5 syntheses or guidelines pooled it, 341 citations in OpenAlex.
- Pooled it
- Recommendations on screening for primary prevention of fragility fractures.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023Guideline
- The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.Archives of osteoporosis · 2023Pooled it
- [Osteoporosis in pneumological diseases : Joint guideline of the Austrian Society for Bone and Mineral Research (ÖGKM) and the Austrian Society for Pneumology (ÖGP)].Wiener klinische Wochenschrift · 2021Guideline
- Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.Drug design, development and therapy · 2019Pooled it
- Adrenalectomy Reduces the Risk of Vertebral Fractures in Patients With Mild Autonomous Cortisol Secretion.The Journal of clinical endocrinology and metabolism · 2025Trial
- Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves' diseases: a case-control study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Trial
- Osteoporosis and adult spinal deformity-a review for spinal surgeons by the SRS adult spinal deformity task force on senescence.Spine deformity · 2026Review
- Pathophysiology and Molecular Signalling in Osteoporosis: Linking Risk Factors to Bone Loss.Journal of cellular and molecular medicine · 2026Review
- Bone health and chronic viral infections: A narrative literature review.World journal of virology · 2026Review
- Corticosteroid use, bone density screening, and the influence of insurance in patients with inflammatory bowel disease: a retrospective analysis.BMC gastroenterology · 2026Article
- Systemic bone loss measured by routine CT is associated with increased pain, postural decompensation, and survival in multiple myeloma.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Long-term effect on bone mineral density of denosumab in the treatment of hyperpituitarism driven osteoporosis: an exploratory study.Pituitary · 2026Article
- The iron-ferroptosis axis in bone homeostasis: a potential complementary pathway for osteoporosis in endometriosis.European journal of medical research · 2026Review
- Osteoporosis After Menopause and After Drug Therapy: The Molecular Mechanism of Bone Loss and Its Treatment.International journal of molecular sciences · 2026Review
- Impact of immunosuppressive therapy and clinical risk factors on the prevalence of low bone mineral density in rheumatic diseases.Frontiers in medicine · 2026Article
- Endocrine-related osteoporosis: bone quality, clinical phenotype, and targeted management.Frontiers in endocrinology · 2026Review
- Chronic Alcohol Consumption Enhances the Differentiation Capacity of Hematopoietic Stem and Progenitor Cells into Osteoclast Precursors.The American journal of pathology · 2026Article
- Postmenopausal Osteoporosis: From Molecular Pathways to Therapeutic Targets-A Mechanism-to-Practice Framework Integrating Pharmacotherapy, Fall Prevention, and Adherence into Patient-Centered Care.Journal of clinical medicine · 2025Review
- Asian Federation of Osteoporosis Societies 2025 consensus on atypical femoral fractures in patients with osteoporosis.Osteoporosis and sarcopenia · 2025Review
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Osteoporosis is a skeletal disorder characterized by decreased mass and compromised bone strength predisposing to an increased risk of fractures. Although idiopathic osteoporosis is the most common form of osteoporosis, secondary factors may contribute to the bone loss and increased fracture risk in patients presenting with fragility fractures or osteoporosis. Several medical conditions and medications significantly increase the risk for bone loss and skeletal fragility. This review focuses on some of the common causes of osteoporosis, addressing the underlying mechanisms, diagnostic approach and treatment of low bone mass in the presence of these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.